January 03, 2025

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer

Imlunestrant, an investigational next-generation oral selective estrogen receptor degrader, significantly improved progression-free survival vs standard of care in patients with ESR1-mutated breast ca...

The ASCO Post

January 03, 2025

Learning From the ZEST Trial in Using ctDNA to Predict Breast Cancer Recurrence

The ZEST clinical trial, designed to evaluate the use of the PARP inhibitor niraparib for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue en...

The ASCO Post

January 03, 2025

De-escalated Neoadjuvant Treatment Adding Nab-Paclitaxel or Docetaxel/Carboplatin to Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer

A Chinese phase III study explored whether de-escalated neoadjuvant treatment with the addition of nab-paclitaxel to trastuzumab/pertuzumab could improve outcomes vs the standard of care in patients w...

The ASCO Post

January 03, 2025

BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery

Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent a bilateral risk-reducing mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of...

The ASCO Post

January 03, 2025

Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence

Patients with early-stage, hormone receptor–positive, HER2-negative breast cancer who are at high risk for recurrence may benefit from adjuvant taxane and anthracycline-containing therapy more than fr...

The ASCO Post

December 19, 2024

Alpelisib Plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer After Previous Therapy

In a cohort of a phase II study (BYLieve) reported in The Lancet Oncology, Rugo et al found that alpelisib plus fulvestrant showed activity in patients with PIK3CA-mutated, hormone receptor–positive, ...

The ASCO Post

December 13, 2024

Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

The ASCO Post

December 12, 2024

Active Monitoring May Be a Viable Option for Some Patients With Low-Risk DCIS

Among patients with hormone receptor–positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar 2-year invasive ipsilateral breast cancer recu...

The ASCO Post

December 12, 2024

Quality of Life Similar Among Patients With Low-Risk DCIS Whether They Received Active Monitoring or Surgery

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring and those who received upfront treatment reported comparable physical, emotional, and psychological outcomes, acc...

The ASCO Post